🇺🇸 FDA
Pipeline program

VX-864

VX19-864-101

Phase 2 small_molecule completed

Quick answer

VX-864 for Alpha1-Antitrypsin Deficiency is a Phase 2 program (small_molecule) at VERTEX PHARMACEUTICALS INC / MA with 1 ClinicalTrials.gov record(s).

Program details

Company
VERTEX PHARMACEUTICALS INC / MA
Indication
Alpha1-Antitrypsin Deficiency
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials